Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A large clinical trial in Africa and Asia has shown that a 7 day course of high dose primaquine, a drug used to treat P. vivax malaria, is well tolerated and just as effective as the current standard 14 day regimen, according to a study published this week in The Lancet. These findings have important implications for the treatment and elimination of vivax malaria in the Asia Pacific.

Dr Bob Taylor, right, in a lab with colleagues at a South Sumatra, Indonesia IMPROV study site © 2019 MORU. Photographer: Prayoon Yuentrakul
Dr Bob Taylor, right, in a lab with colleagues at a South Sumatra, Indonesia IMPROV study site

Coordinated by the Menzies School of Health Research (Menzies, Darwin, Australia), the Mahidol Oxford Tropical Medicine Research Unit (MORU, Bangkok, Thailand) and the Eijkman Institute of Molecular Biology (Jakarta, Indonesia), the IMPROV (Improving the Radical Cure of Vivax Malaria) trial involved > 2,000 patients in Ethiopia, Afghanistan, Indonesia and Vietnam and tested the treatment effectiveness of a high-dose 7 day course of primaquine.

Its findings challenge the standard treatment regimen that has been widely used for the last 60 years.

The WHO recommends that patients with P. vivax malaria are treated with antimalarial drugs to clear the parasites in the blood followed by a 14-day course of primaquine to kill the liver hypnozoites and prevent recurrent bouts of malaria.

Associate Senior Clinical Research Fellow Dr Bob Taylor, MORU, says adherence to the standard 14-day regimen is poor.

“Primaquine is the only widely available drug that kills the P. vivax hypnozoites in the liver, but patients often fail to complete the treatment once they feel better. We found that the 7-day high-dose course of primaquine was as effective as the recommended 14-day treatment,” Dr Taylor said.

P. vivax malaria is a major cause of illness in Asia, Oceania, the Horn of Africa, and the Americas. The P. vivax parasites has dormant forms in the liver called hypnozoites, that wake up weeks to months later causing relapses - multiple episodes of malaria that lead to repeated illness and time out of work and school.

Senior Researcher Dr Kamala Thriemer (Menzies) says a shorter treatment prevents multiple episodes of malaria that lead to ill health particularly in young children and pregnant women.

“The shorter, 7 day primaquine regimen worked very well, with very few people having another episode of malaria within 12 months. Although some patients had minor side effects, the drug was generally well tolerated,” Dr Thriemer said.

The study’s principal investigator Prof Ric Price (University of Oxford) said: “Vivax malaria is becoming the predominant cause of malaria in the Asia Pacific. A short course primaquine regimen is much easier to administer and patients are more likely to complete treatment.

“If used widely, this new regimen could help reduce and accelerate the elimination of vivax malaria from the region,” said Prof Price.

Reference

Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Taylor et al, The Lancet.

Funders

This research was funded by the: UK Department for International Development, UK Medical Research Council, UK National Institute for Health Research, and the Wellcome Trust through the Joint Global Health Trials Scheme (MR/K007424/1) and the Bill & Melinda Gates Foundation (OPP1054404).

Similar stories

Laos’ first Pint of Science: warty newts, COVID, AI for Instagram, and more!

Organised by a grass-root community of thousands of scientists across the world, Pint of Science 2022 allowed researchers in 25 countries and over 800 cities to share their latest findings with lay folk in interesting, informal settings. Lao PDR joined the global Pint of Science family on Monday 9 May, when the first-ever Pint of Science Laos kicked off!

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

PRIORITISE study team publishes results, now seeks partners

In regions where few people have received Covid-19 vaccines, health systems remain vulnerable to surges in SARS-CoV-2 infections. During the delta-wave of COVID-19 in India, for example, healthcare facilities and staff across the country struggled to cope with the surge in the number of cases of COVID-19 due to a shortage of hospital beds for people with severe cases, plus shortages of medicines and limited human resources.

Under the Mask, drama film based on testimonies of tuberculosis patients

In 2022, tuberculosis (TB) remains a major global health problem, particularly in developing countries. On the Thai-Myanmar border, TB is an important problem among migrants, a vulnerable, very mobile population, with unstable, often difficult living conditions, insecure incomes, and poor access to health services.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Study finds steady increase in WHO-validated artemisinin resistance markers in Asia

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.